Agnico Eagle Mines Limited
reported net income of $136.1 million or 56 cents per share in first-quarter 2021, against a net loss of $21.6 million or 9 cents per share reported in the year-ago quarter.
Barring one-time items, adjusted earnings per share came in at 67 cents, surpassing the Zacks Consensus Estimate of 56 cents per share.
The company generated revenues of $934.4 million, up 39.1% year over year. The figure topped the Zacks Consensus Estimate of $889.
Payable gold production was up 25.63% year over year to 516,804 ounces in the reported quarter. The figure includes gold production at Hope Bay. Total cash costs per ounce for gold were $734, down 12.2% year over year.
All-in sustaining costs (AISC) were $1,007 per ounce in the quarter, including Hope Bay.
Agnico Eagle ended the quarter with cash and cash equivalents of $126.5 million compared with $402.5 million as of Dec 31, 2020. Long-term debt was around $1,565.8 million as of Mar 31,2021, compared with $1,565.2 million as of Dec 31, 2020.
Total cash from operating activities amounted to $356.4 million in the first quarter, up 118% year over year.
The company expects gold production for 2021 to be 2,047,500 ounces. It also expects total cash costs per ounce of $700-$750 and AISC of $950-$1,000 per ounce in 2021.
The second quarter is expected to have the weakest production. This is due to scheduled maintenance at several operations in the second quarter, which results in changes in the mining sequence. This brings in slightly lower grades.
Shares of Agnico Eagle have declined 1.5% in the past year compared with 10.3% decline of the
Zacks Rank & Key Picks
Agnico Eagle currently carries a Zacks Rank #4 (Sell).
Dow has a projected earnings growth rate of roughly 261.5% for the current year. The company’s shares have surged 89.1% in a year. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see
the complete list of today’s Zacks #1 Rank stocks here.
Nucor has an expected earnings growth rate of around 228.4% for the current year. The company’s shares have gained 100.4% in the past year. It currently sports a Zacks Rank #1.
Impala has an expected earnings growth rate of 197.6% for the current fiscal. The company’s shares have skyrocketed 235.4% in the past year. It currently flaunts a Zacks Rank #1.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report